ESAIY / Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

This segment originally aired on October 26, 2023. Eisai has (EISAY) reported positive results in clinical trials of their Alzheimer's drug- Leqembi. more_horizontal

Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet thei more_horizontal

Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF more_horizontal

Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head more_horizontal

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer fail more_horizontal

Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and more_horizontal

The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the more_horizontal

TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the more_horizontal